Ethyl Acetate

Ethyl Acetate

SCHEMBL58459

CC(Cl)Cl.CC(Cl)Cl.CC(Cl)Cl.CC(Cl)Cl.CC(Cl)Cl.CC(Cl)Cl.CC(Cl)Cl.CC(Cl)Cl.CC(Cl)Cl.CCOC(C)=O

nearest known ligand 0.74

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.74
LMNA P02545 2/20 0.74
HSD17B10 Q99714 1/20 0.74
TSHR P16473 2/20 0.46
ALOX15 P16050 2/20 0.42
MGAM O43451 1/20 0.42
GAA P10253 1/20 0.42
SI P14410 1/20 0.42
MGAM2 Q2M2H8 1/20 0.42
SOAT1 P35610 1/20 0.42
TRPA1 O75762 1/20 0.39
GLO1 Q04760 1/20 0.38
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA9 Q16790 1/20 0.36
PGR P06401 1/20 0.36
CHRM2 P08172 1/20 0.36
CHRM4 P08173 1/20 0.36
HTR1A P08908 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ethyl Acetate SCHEMBL7266603 1.00 ALDH1A1 (0.74) ALDH1A1LMNAHSD17B10TSHRALOX15
Ethyl Acetate SCHEMBL9486136 1.00 ALDH1A1 (0.74) ALDH1A1LMNAHSD17B10TSHRALOX15
Ethyl Acetate SCHEMBL6713360 1.00 ALDH1A1 (0.74) ALDH1A1LMNAHSD17B10TSHRALOX15
Ethyl Acetate SCHEMBL1802039 1.00 ALDH1A1 (0.74) ALDH1A1LMNAHSD17B10TSHRALOX15
Ethyl Acetate SCHEMBL6717750 1.00 ALDH1A1 (0.74) ALDH1A1LMNAHSD17B10TSHRALOX15
Ethyl Acetate SCHEMBL7664143 0.97 ALDH1A1 (0.70) ALDH1A1LMNAHSD17B10TSHRALOX15
Ethyl Acetate SCHEMBL28113634 0.93 ALDH1A1 (0.64) ALDH1A1LMNAHSD17B10TSHRALOX15
Ethyl Acetate SCHEMBL11181789 0.92 ALDH1A1 (0.78) ALDH1A1LMNAHSD17B10TSHRALOX15
Ethyl Acetate SCHEMBL10364372 0.92 ALDH1A1 (0.78) ALDH1A1LMNAHSD17B10TSHRALOX15
Ethyl Acetate SCHEMBL6268192 0.92 ALDH1A1 (0.78) ALDH1A1LMNAHSD17B10TSHRALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2644599-B1 Method for preparing a 2-halo-4-nitroimidazole compound OTSUKA PHARMA CO LTD (JP) 2014-12-10 EP disclosed
EP-2644599-A1 Method for preparing 1-substituted-4-nitroimidazole compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-10-02 EP disclosed
US-20120130082-A1 1-Substituted-4-Nitroimidazole Compound and Method for Preparing the Same OTSUKA PHARMACEUTICAL CO., LTD. 2012-05-24 US disclosed
US-8129544-B2 Preparation of 4-nitroimidazoles that are 2-substituted with a halo or optionally oxidized phenylthio group and 1-substituted with hydrogen, an oxiranylmethyl-, or a phenyl- group; dehalogenation, reduction, nitration, rearrangement OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-03-06 US disclosed
US-7807843-B2 1-substituted-4-nitroimidazole compound and method for preparing the same OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-10-05 US disclosed
US-20080200689-A1 1-Substituted-4-nitroimidazole compound and method for preparing the same OTSUKA PHARMACEUTICAL CO., LTD. 2008-08-21 US disclosed
US-7368579-B2 1-substituted-4-nitroimidazole compound and process for producing the same OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2008-05-06 US disclosed
US-20080097107-A1 1-substituted-4-nitroimidazole compound and method for preparing the same OTSUKA PHARMACEUTICAL CO. LTD. 2008-04-24 US disclosed
US-20060079697-A1 1-substituted-4-nitroimidazole compound and process for producing the same OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-04-13 US disclosed
EP-1553088-A1 1-SUBSTITUTED 4-NITROIMIDAZOLE COMPOUND AND PROCESS FOR PRODUCING THE SAME Otsuka Pharmaceutical Company, Limited (JP) 2005-07-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120130082-A1 1-Substituted-4-Nitroimidazole Compound and Method for Preparing the Same CBR1, CBR3, DCXR ALDH1A1 836/4885LMNA 2700/4885HSD17B10 1406/4885
US-20060079697-A1 1-substituted-4-nitroimidazole compound and process for producing the same CBR1, CBR3, DCXR ALDH1A1 780/4885LMNA 3395/4885HSD17B10 1184/4885
US-20080200689-A1 1-Substituted-4-nitroimidazole compound and method for preparing the same CBR1, CBR3, DCXR ALDH1A1 836/4885LMNA 2700/4885HSD17B10 1406/4885
US-20080097107-A1 1-substituted-4-nitroimidazole compound and method for preparing the same CBR1, CBR3, DCXR ALDH1A1 836/4885LMNA 2700/4885HSD17B10 1406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.